Alkermes plc has entered into a definitive agreement to acquire Rodin Therapeutics, Inc., a privately held biopharma company focused on small molecule therapeutics for synaptopathies. This transaction expands Alkermes’ experience in central nervous system (CNS) diseases and development efforts into a wide range of neurodegenerative disorders.  Rodin has been working to develop first-in-class, orally-available, brain-permeable therapeutics for synaptopathies by designing molecules that t...